On August 19th, the Health Workers For All Coalition – which Wemos co-chairs – held a webinar. During this webinar, Wemos’ global health advocate Corinne Hinlopen and Genevieve Gencianos of Public Services International shared their insights on the ongoing review of the WHO Code of Practice on the International Recruitment of Health Personnel.
1.9 million Euro. It is expected that that will be the price of the medicine Zolgensma, manufactured by the pharmaceutical company Novartis. At the end of this month, the European Medicines Agency (EMA) will give approval for this medicine. The Dutch newspaper De Telegraaf recently interviewed our global health advocate Ella Weggen about how the current medicines policy in the Netherlands has made the ludicrously high price of 1.9 million Euro possible.
The report ‘Overpriced’, which we published together with partner organisation SOMO in May, shows how Dutch tax money is used for the development of new medicines in the Netherlands. We have issued a joint response with SOMO, in reaction to Minister Bruin’s answers to parliamentary questions about the findings of our report.